BPC-157

BPC-157 (also known as PL 14736) is a pentadecapeptide. It has the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.[1] This peptide is a sequence of 98 hydrogen, 62 carbon, 22 oxygen, and 16 nitrogen atoms (molecular formula is C62-H98-N16-O22). The PUBCHEM ID is CID 108101.[2] The acronym in BPC peptide stands for “Body Protecting Compound”. The body naturally produces BPCs in the gut and stomach which serve to protect the organs from the unwanted activity and helps them heal.[3]

It has been tested in animal trials for cytoprotective and wound healing activities.[4][5] BPC-157 can contribute to wound healing due to muscle and tendon rejuvenating properties through accelerating the rate of angiogenic repair.[6]

BPC-157 & Wound Healing Research

The mucosal barrier in the GI tract helps to protect the underlying tissues from the harmful actions of bile, gastric acid, and other compounds necessary for digestion and absorption of nutrients from food. BPC helps to preserve the structural integrity of the mucosal layer. The role is partially mediated through the recruitment of fibroblasts. Fibroblasts are pivotal to the healing of wounds as they produce extracellular matrix proteins such as fibrin, collagen, and elastin including others. BPC-157 has been observed to promote proliferation and faster migration of fibroblasts in a dose-dependent manner, both in culture and in vivo.[7]


References
  1. Jelovac, Nikola; Sikiric, Predrag; Rucman, Rudolf; Petek, Marijan; Marovic, Anton; Perovic, Darko; Seiwerth, Sven; Mise, Stjepan; Turkovic, Branko; Dodig, Goran; Miklic, Pavle; Buljat, Gojko; Prkacin, Ingrid (1999). "Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats". European Journal of Pharmacology. 379: 19–31. doi:10.1016/S0014-2999(99)00486-0. PMID 10499368.
  2. "PUBCHEM". pubchem.ncbi.nlm.nih.gov. Retrieved 4 February 2021.
  3. "BPC 157 Peptide: Benefits, Side Effects & Research". Sport Peptides. Retrieved 14 January 2021.
  4. Sikiric, P.; Seiwerth, S.; Brcic, L.; Blagaic, A. B.; Zoricic, I.; Sever, M.; Klicek, R.; Radic, B.; Keller, N.; Sipos, K.; Jakir, A.; Udovicic, M.; Tonkic, A.; Kokic, N.; Turkovic, B.; Mise, S.; Anic, T. (2006). "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response". Inflammopharmacology. 14 (5–6): 214–21. doi:10.1007/s10787-006-1531-7. PMID 17186181. S2CID 24132425.
  5. Cerovecki, Tomislav; Bojanic, Ivan; Brcic, Luka; Radic, Bozo; Vukoja, Ivan; Seiwerth, Sven; Sikiric, Predrag (September 2010). "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat". Journal of Orthopaedic Research. 28 (9): 1155–1161. doi:10.1002/jor.21107. ISSN 1554-527X. PMID 20225319. S2CID 22085833.
  6. "BPC-157 Regeneration Peptide - The Science, Reviews and Dosage and How It Is Used". Vitamonk. Retrieved 1 April 2018.
  7. "BPC-157 Peptide". BiotechPeptides. Retrieved 4 February 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.